他诺莫司（tacrolimus）以往称为FK506，现美国FDA已准可接受肝移植的病人作为器官排斥的初期预防措施。本品对环抱菌素和其它免疫抑制剂无效的器官移植排斥可作为挽救措施。1作用和药动学本品是一种与环孢菌素具有相同活性但无化学相似性的细菌衍生的大环内酯化合物。它能抑制 Tacrolimus, formerly known as FK506, is now the initial prophylaxis of organ rejection in the US FDA for patients who have been approved for liver transplantation. The product of cyclosporine and other immunosuppressive agents invalid organ transplant rejection can be used as a rescue measure. 1 role and pharmacokinetics This product is a cyclosporin with the same activity but no chemical similarity of bacterial-derived macrolide compounds. It can be suppressed